SCHEMBL1379374

SCHEMBL1379374

Cc1nc(-c2ccccc2)c(C(=O)N2CCN(c3cccc(C(N)=O)c3)CC2)s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.47
MAPT P10636 2/20 0.47
USP2 O75604 1/20 0.47
LMNA P02545 1/20 0.47
MAPK1 P28482 1/20 0.47
PARP14 Q460N5 1/20 0.46
PARP10 Q53GL7 1/20 0.46
CKS1B P61024 1/20 0.45
SKP1 P63208 1/20 0.45
SKP2 Q13309 1/20 0.45
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
POLB P06746 1/20 0.44
SLC6A7 Q99884 1/20 0.44
GAA P10253 1/20 0.43
BTK Q06187 1/20 0.43
SCD O00767 2/20 0.43
SCD5 Q86SK9 1/20 0.43
ALDH1A1 P00352 3/20 0.43
HPGD P15428 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1383839 0.89 LMNA (0.48) TSHRMAPTUSP2LMNAMAPK1
SCHEMBL1382338 0.89 USP2 (0.48) TSHRMAPTUSP2LMNAMAPK1
SCHEMBL1381703 0.82 TP53 (0.53) TSHRMAPTLMNAKMT2AMEN1
SCHEMBL1379595 0.81 ADORA2A (0.47) TSHRMAPTUSP2LMNAPARP14
SCHEMBL1385439 0.76 USP2 (0.48) TSHRMAPTUSP2LMNAMAPK1
SCHEMBL1384633 0.76 USP2 (0.47) TSHRMAPTUSP2LMNAMAPK1
SCHEMBL1380130 0.76 USP2 (0.47) TSHRMAPTUSP2LMNAMAPK1
SCHEMBL1383039 0.75 CHEK2 (0.46) TSHRMAPTUSP2LMNAMAPK1
SCHEMBL1383740 0.75 ALDH1A1 (0.46) TSHRMAPTUSP2LMNAMAPK1
SCHEMBL5751904 0.75 CYP1A2 (0.47) TSHRMAPTUSP2LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4805813-B2 2011-11-02 JP claimed
EP-1641765-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2006-04-05 EP claimed
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AVENTIS PHARMA S.A. (FR) 2005-01-20 US claimed
WO-2004108685-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-12-16 WO claimed
EP-1641765-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF Aventis Pharma S.A. (FR) 2006-04-05 EP disclosed
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AVENTIS PHARMA S.A. (FR) 2005-01-20 US disclosed
WO-2004108685-A1 ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014765-A1 Aryl-heteroaromatic products, compositions comprising them and use AHR, ARNT, MYC TSHR 3838/4885MAPT 3583/4885USP2 2195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.